Vial spec // no validated dose
KLOW peptide: dosage in the research context
What can be stated is a vial composition, not a dose. Combination PK: NO DATA. Everything here describes research handling, never a human protocol.
The short version
There is no validated human dose for KLOW peptide, and this page does not supply one. What can be stated honestly is a vial spec — how the research blend is composed and handled in a lab — not an amount for a person. The canonical research vial is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. That number describes what is in the vial, not what anyone should use. Two reasons there is no "KLOW dose": first, the blend was never tested, so no study established one; second, the four peptides clear the body at very different speeds, so their separate research amounts cannot be added into a single figure. Below: the vial composition, how it is reconstituted (mixed with sterile water) for lab handling, and the half-life mismatch — all in research terms only, third person, no instructions.
KLOW peptide dosage in the research context
The KLOW peptide dosage that circulates is, in fact, a vial-composition figure: the most widely listed research vial is 80 mg total at a 50/10/10/10 mg ratio (GHK-Cu / BPC-157 / TB-500 / KPV) reconstituted with bacteriostatic water for laboratory handling [4]. No validated human dosing exists for the blend, and component-level research doses differ widely by species and route and are not additive into a single "KLOW dose." In the component literature, amounts were administered to animals or cells in study-specific units — for example, BPC-157 was given to rats at 10 microgram, 10 nanogram or 10 picogram per animal in the transected-tendon work [2], and KPV acted at nanomolar concentrations in epithelial cells [3]. These are research conditions, not protocols, and they do not translate into a human figure for the blend.
How a KLOW dose is described in research handling
When a KLOW dosage is described at all, it is described as a research-handling quantity drawn from the reconstituted vial, not a clinical dose. The honest framing is the vial: 80 mg total across four constituents, of which GHK-Cu is ~62.5% by mass. Because the four peptides have markedly different reported half-lives — the tripeptides KPV and GHK-Cu clear far faster than the larger BPC-157, and the TB-500 fragment differs from native thymosin beta-4 [7] — there is no single exposure window that holds all four constant. Any attempt to express "a KLOW dose" as one number therefore obscures the pharmacokinetic mismatch baked into the formulation. The literature supports describing the vial; it does not support describing a dose.
How KLOW is reconstituted for research handling
KLOW reconstitution, in research handling, means rehydrating the lyophilized (freeze-dried) blend with bacteriostatic water; the resulting solution is typically refrigerated [4]. One chemistry note belongs here: copper(II) in GHK-Cu can participate in redox reactions, a theoretical compatibility consideration when it is co-dissolved with three other peptides in one vial — a question that has not been formally characterized for this specific mixture. The characteristic blue tint of a reconstituted KLOW solution comes from that copper(II): copper(II) solutions are blue, so the color is a property of the GHK-Cu component, not a marker of activity or potency. This is handling and stability information, not an administration instruction.
Routes studied and the absence of a combination protocol
Across the component literature, subcutaneous injection appears in research handling, while individual constituents were also studied by other routes — topical for GHK-Cu, oral and targeted delivery for KPV and BPC-157, and intra-articular for BPC-157 [3][6]. Critically, none of these route studies tested the four-peptide combination; they are single-component findings. There is no validated dosing frequency for the blend either, because the component half-lives differ too much for one co-formulated schedule to be evidence-based [7]. The consistent answer to "how is KLOW dosed" is therefore the same across every framing: there is a vial composition on record and no human protocol on record.